Provided by Tiger Trade Technology Pte. Ltd.

Boston Scientific

48.30
+1.463.12%
Post-market: 48.300.00000.00%16:10 EDT
Volume:18.18M
Turnover:875.63M
Market Cap:70.00B
PE:19.57
High:48.97
Open:46.40
Low:46.09
Close:46.84
52wk High:109.50
52wk Low:42.20
Shares:1.45B
Float Shares:1.45B
Volume Ratio:0.83
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.47
EPS(LYR):1.94
ROE:15.34%
ROA:6.19%
PB:2.81
PE(LYR):24.90

Loading ...

Boston Scientific CEO Michael F. Mahoney Acquires Common Shares Worth $10.06 Million

Reuters
·
Aug 06

Movement Alert|Boston Scientific Falls 3.03% in Regular Trading, Full-Year Guidance Cut and Multiple Analyst Target Reductions Continue to Weigh

Market Focus
·
Aug 05

Boston Scientific’s Long-Term ESG Study: What Termination Means for Obesity Investment Sentiment

TIPRANKS
·
Aug 05

Boston Scientific Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 04

Boston Scientific Director Edward J. Ludwig Buys 5,000 Shares for $227,399.50

Reuters
·
Aug 04

Movement Alert|Boston Scientific Rises 3.72% in Regular Trading, Trading at $48.685

Market Focus
·
Aug 03

Boston Scientific FY26 Q2 Net Income Rises 13.8% to 907 Million; Net Sales Climb 7.5% to 5.44 Billion

Reuters
·
Aug 03

Why Boston Scientific (BSX) Is Up 5.6% After Mixed Q2, Recall News And Guidance Update

Simply Wall St.
·
Aug 02

Boston Scientific Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 01

Movement Alert|Boston Scientific Falls 3.13% in Regular Trading, Argus Downgrades Rating to Hold Extending Post-Earnings Selling Pressure

Market Focus
·
Jul 31

Argus Downgrades Boston Scientific to Hold From Buy

MT Newswires Live
·
Jul 31

Boston Scientific Cut to Hold from Buy by Argus Research

Dow Jones
·
Jul 31

Boston Scientific Corp : Argus Research Cuts to Hold from Buy

THOMSON REUTERS
·
Jul 31

Boston Scientific (BSX) Stock Ignores Margin Strength As Growth Outlook Softens

Simply Wall St.
·
Jul 31

U.S. Research ROUNDUP-Apple, Amazon, Mastercard

Reuters
·
Jul 31

Penumbra Q2 FY26 Net Income Falls to 34.81 Million; Revenue Rises 14.9% to 390 Million

Reuters
·
Jul 31

Penumbra Q2 Revenue Slightly Beats Estimates, Helped by Product Segment Increase

Reuters
·
Jul 31

Cerus Q2 Adjusted Ebitda Misses Estimates, Raises 2026 Outlook

Reuters
·
Jul 31

Penumbra - Will not Provide Full Year 2026 Guidance or Host Conference Call Due to Pending Acquisition

THOMSON REUTERS
·
Jul 31

Boston Scientific's Watchman Slowdown Raises Utilization Questions, Oppenheimer Says

MT Newswires Live
·
Jul 31